deCODE biostructures Announces Expansion of Collaboration with Replidyne to Include Fragments of Life™
News Nov 19, 2007
deCODE also announces the signing of an extension to the collaborative research agreement with Replidyne.
Under the terms of the extension, deCODE biostructures will continue to deliver ligand-bound structures and continue gene-to-structure collaborative research on additional proprietary targets.
The research fee and milestone-based collaboration provides Replidyne with access to deCODE's expertise in protein crystal structure determination and to deCODE's computational chemistry assets.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE